跳轉至內容
Merck
全部照片(1)

文件

S1200000

螺内酯

European Pharmacopoeia (EP) Reference Standard

同義詞:

4-孕烷-21-油酸-17α-醇-3-酮-7α-硫醇γ-内酯7-乙酸盐, 7α-(乙酰硫基)-17α-羟基-3-氧杂戊烯-4-烯-21-羧酸γ-内酯

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C24H32O4S
CAS號碼:
52-01-7
分子量：:
416.57
MDL號碼:
MFCD00082250
分類程式碼代碼:
41116107
PubChem物質ID:
329824467
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

spironolactone

製造商／商標名

EDQM

mp

207-208 °C (lit.)

應用

pharmaceutical (small molecule)

格式

neat

SMILES 字串

CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]45CCC(=O)O5)[C@H]13

InChI

1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1

InChI 密鑰

LXMSZDCAJNLERA-ZHYRCANASA-N

基因資訊

human ... NR3C2(4306)

尋找類似的產品？ 前往 產品比較指南

一般說明

本品按现行药典规定交付。所有为支持本产品而提供的信息，包括SDS和任何产品信息单均由药典颁发机构制定并发布。 如需进一步信息和支持，请访问现行药典网站。

應用

螺内酯EP参考标准品的预期用途是欧洲药典规定的实验室测试。

生化／生理作用

螺内酯是竞争性醛固酮受体拮抗剂。 用作保钾利尿剂。

包裝

本品按照现行药典要求提供。有关当前单位数量，请见EDQM 参考目录。

其他說明

可能适用相应的销售限制。

象形圖

Health hazard
GHS08

訊號詞

Danger

危險聲明

H351,H360FD,H373

危險分類

Carc. 2 - Repr. 1B - STOT RE 2

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

Choose from one of the most recent versions:

分析證明 (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客戶支援

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Aldosterone inhibition in patients with heart failure with preserved ejection fraction.
Lars H Lund et al.
JAMA, 310(2), 205-205 (2013-07-11)
Adam D Karns et al.
Journal of clinical hypertension (Greenwich, Conn.), 15(3), 186-192 (2013-03-06)
Aldosterone inhibition with mineralcorticoid receptor antagonists (MRAs) is an effective treatment for resistant hypertension. Aldosterone synthase inhibitors (ASIs) are currently being investigated as a new therapeutic strategy to reduce aldosterone secretion from the adrenal gland. In this study, the efficacy
Aldosterone inhibition in patients with heart failure with preserved ejection fraction.
Christopher J A Neil et al.
JAMA, 310(2), 204-204 (2013-07-11)
Yang Li et al.
Journal of gastroenterology and hepatology, 35(6), 1069-1077 (2019-12-21)
Emerging evidence suggests aldosterone (aldo) and NLRP3 inflammasome are important factors for HSC activation and liver fibrosis. However, the interaction between aldo and NLRP3 inflammasome in HSC activation and liver fibrosis remains largely unknown. The aim of this study is
Alexander Gabor et al.
Hypertension (Dallas, Tex. : 1979), 61(5), 1083-1090 (2013-03-20)
A chronic increase in circulating angiotensin II (Ang II) activates an aldosterone-mineralocorticoid receptor-ouabain neuromodulatory pathway in the brain that increases neuronal activation in hypothalamic nuclei, such as the paraventricular nucleus (PVN) and causes progressive hypertension. Several models of chronic sympathetic
查看所有相關論文

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務